Enhancingin vitro antibody production rate per cell by applying mouse peritoneal factors

1991 ◽  
Vol 13 (4) ◽  
pp. 255-260 ◽  
Author(s):  
T. Mikami ◽  
F. Makishima ◽  
E. Suzuki
Keyword(s):  
Production Rate ◽  
Antibody Production ◽  
Antibody Production Rate

Functional proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate

2006 ◽  
Vol 94 (5) ◽  
pp. 830-841 ◽  
Author(s):  
Diane M. Dinnis ◽  
Scott H. Stansfield ◽  
Stefan Schlatter ◽  
C. Mark Smales ◽  
Daniel Alete ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Production Rate ◽  
Cell Lines ◽  
Antibody Production ◽  
Proteomic Analysis ◽  
Myeloma Cell ◽  
Monoclonal Antibody Production ◽  
Recombinant Monoclonal Antibody ◽  
Antibody Production Rate

scholarly journals Characterising heterogeneity and sero-reversion in antibody responses to mild SARS⍰CoV-2 infection: a cohort study using time series analysis and mechanistic modelling

2020 ◽  
Author(s):  
C Manisty ◽  
TA Treibel ◽  
M Jensen ◽  
A Semper ◽  
G Joy ◽  
...  
Keyword(s):  
Production Rate ◽  
Humoral Immunity ◽  
Antibody Production ◽  
Nucleocapsid Protein ◽  
Care Workers ◽  
Antibody Production Rate ◽  
Antibody Titres ◽  
Antibody Levels ◽  
Incident Infection

AbstractBackgroundSARS-CoV-2 serology is used to identify prior infection at individual and at population level. Extended longitudinal studies with multi-timepoint sampling to evaluate dynamic changes in antibody levels are required to identify the time horizon in which these applications of serology are valid, and to explore the longevity of protective humoral immunity.MethodsHealth-care workers were recruited to a prospective cohort study from the first SARS-CoV-2 epidemic peak in London, undergoing weekly symptom screen, viral PCR and blood sampling over 16-21 weeks. Serological analysis (n=12,990) was performed using semi-quantitative Euroimmun IgG to viral spike S1 domain and Roche total antibody to viral nucleocapsid protein (NP) assays. Comparisons were made to previously reported pseudovirus neutralising antibody measurements.FindingsA total of 157/729 (21.5%) participants developed positive SARS-CoV-2 serology by one or other assay, of whom 31.0% were asymptomatic and there were no deaths. Peak Euroimmun anti-S1 and Roche anti-NP measurements correlated (r=0.57, p<0.0001) but only anti-S1 measurements correlated with near-contemporary pseudovirus neutralising antibody titres (measured at 16-18 weeks, r=0.57, p<0.0001). By 21 weeks’ follow-up, 31/143 (21.7%) anti-S1 and 6/150 (4.0%) anti-NP measurements reverted to negative. Mathematical modelling suggested faster clearance of anti-S1 compared to anti-NP (median half-life of 2.5 weeks versus 4.0 weeks), earlier transition to lower levels of antibody production (median of 8 versus 13 weeks), and greater reductions in relative antibody production rate after the transition (median of 35% versus 50%).InterpretationMild SARS-CoV-2 infection is associated with heterogenous serological responses in Euroimmun anti-S1 and Roche anti-NP assays. Anti-S1 responses showed faster rates of clearance, more rapid transition from high to low level production rate and greater reduction in production rate after this transition. The application of individual assays for diagnostic and epidemiological serology requires validation in time series analysis.FundingCharitable donations via Barts CharityResearch in contextEvidence before this studyWe searched PubMed, medRxiv, and bioRxiv for [“antibody” OR “serology”] AND [“SARS-CoV-2” OR “COVID-19”]. The available literature highlights widespread use of serology to detect recent SARS-CoV-2 infection in individual patients and in population epidemiological surveys. Antibody to virus spike protein S1 domain is widely reported to correlate with neutralising antibody titres. The existing assays have good sensitivity to detect seroconversion within 14 days of incident infection, but the available longitudinal studies have reported variable rates of decline in antibody levels and reversion to undetectable levels in some people over 3 months. High frequency multi-time point serology data for different antibody targets or assays in longitudinal cohorts from the time of incident infection to greater than 3 months follow up are lacking.Added value of this studyWe combine detailed longitudinal serology using the Euroimmun anti-S1 and Roche anti-nucleocapsid protein (NP) assays in 731 health care workers from the time of the first SARS-CoV-2 epidemic peak in London, UK. In 157 seroconverters (using either assay) we show substantial heterogeneity in semiquantitative antibody measurements over time between individuals and between assays. Mathematical modelling of individual participant antibody production and clearance rates in individuals with at least 8 data points over 21 weeks showed anti-S1 antibodies to have a faster clearance rate, earlier transition from the initial antibody production rate to lower rates, and greater reduction in antibody production rate after this transition, compared to anti-NP antibodies as measured by these assays. As a result, Euroimmun anti-S1 measurements peaked earlier and then reduced more rapidly than Roche anti-NP measurements. In this study, these differences led to 21% anti-S1 sero-reversion, compared to 4% anti-NP sero-reversion over 4-5 months.Implications of all of the available evidenceThe rapid decline in anti-S1 antibodies measured by the Euroimmun assay following infection limits its application for diagnostic and epidemiological screening. If generalisable, these data are consistent with the hypothesis that anti-S1 mediated humoral immunity may not be sustained in some people beyond the initial post-infective period. Further work is required to understand the mechanisms behind the heterogeneity in antibody kinetics between individuals to SARS-CoV-2. Our data point to differential mechanisms regulating humoral immunity against these two viral targets.

The enhancement of specific antibody production rate in glucose- and glutamine-controlled fed-batch culture

1992 ◽  
Vol 8 (1) ◽  
pp. 75-84 ◽  
Author(s):  
Takeshi Omasa ◽  
Masaru Ishimoto ◽  
Ken-ichi Higashiyama ◽  
Suteaki Shioya ◽  
Ken-ichi Suga
Keyword(s):  
Production Rate ◽  
Batch Culture ◽  
Antibody Production ◽  
Specific Antibody ◽  
Fed Batch ◽  
Antibody Production Rate ◽  
Specific Antibody Production ◽  
Fed Batch Culture

Correlation of antibody production rate with glucose and lactate metabolism in Chinese hamster ovary cells

2011 ◽  
Vol 34 (3) ◽  
pp. 425-432 ◽  
Author(s):  
Fei Chen ◽  
Zhaoyang Ye ◽  
Liang Zhao ◽  
Xuping Liu ◽  
Li Fan ◽  
...  
Keyword(s):  
Production Rate ◽  
Antibody Production ◽  
Chinese Hamster Ovary ◽  
Chinese Hamster Ovary Cells ◽  
Chinese Hamster ◽  
Lactate Metabolism ◽  
Ovary Cells ◽  
Antibody Production Rate

Dry chip feedrate control using online chip moisture

TAPPI Journal ◽  
2018 ◽  
Vol 17 (05) ◽  
pp. 295-305
Author(s):  
Wesley Gilbert ◽  
Ivan Trush ◽  
Bruce Allison ◽  
Randy Reimer ◽  
Howard Mason
Keyword(s):  
Production Rate ◽  
Control Strategy ◽  
Rate Control ◽  
Near Infrared ◽  
Dry Mass ◽  
The Other ◽  
Process Variability ◽  
Moisture Sensor ◽  
Feedback Control Strategy ◽  
And Control

Normal practice in continuous digester operation is to set the production rate through the chip meter speed. This speed is seldom, if ever, adjusted except to change production, and most of the other digester inputs are ratioed to it. The inherent assumption is that constant chip meter speed equates to constant dry mass flow of chips. This is seldom, if ever, true. As a result, the actual production rate, effective alkali (EA)-to-wood and liquor-to-wood ratios may vary substantially from assumed values. This increases process variability and decreases profits. In this report, a new continuous digester production rate control strategy is developed that addresses this shortcoming. A new noncontacting near infrared–based chip moisture sensor is combined with the existing weightometer signal to estimate the actual dry chip mass feedrate entering the digester. The estimated feedrate is then used to implement a novel feedback control strategy that adjusts the chip meter speed to maintain the dry chip feedrate at the target value. The report details the results of applying the new measurements and control strategy to a dual vessel continuous digester.

CORTICOSTEROID-UMSATZ UND CORTICOSTEROID-PRODUKTION BEI RATTEN UNTER DER BEHANDLUNG MIT ANABOLEN STEROIDEN

1965 ◽  
Vol 48 (2) ◽  
pp. 263-271 ◽  
Author(s):  
Herbert Schriefers ◽  
Gerlinde Scharlau ◽  
Franzis Pohl
Keyword(s):  
Production Rate ◽  
Adult Female ◽  
Anabolic Steroids ◽  
Reduction Rate ◽  
Female Rats ◽  
Adrenal Weight ◽  
Hydrogenase Activity ◽  
Anabolic Effect ◽  
Liver Slices

ABSTRACT After the administration of anabolic steroids to adult female rats in daily doses of 1 mg per animal for 14 days, the following parameters were investigated: the rate of the Δ4-5α-hydrogenase-catalyzed cortisone reduction in liver slices and microsomal fractions, the adrenal weight and the in vitro corticosterone production rate. Among the steroids tested, only 17α-methyl-testosterone and 17α-ethyl-19-nor-testosterone were effective in lowering significantly cortisone reduction rate by liver slices with concomitant decreases in microsomal Δ4-5α-hydrogenase-activity. Testosterone, 19-nor-testosterone, 17α-ethinyl-19-nor-testosterone, 17α-methyl-17β-hydroxy-androsta-1,4-dien-3-one and 1-methyl-17β-hydroxy-androst-1-en-3-one were ineffective or only slightly effective. Adrenal weight and absolute corticosterone production rate (μg/60 min per animal) were decreased after treatment with 17α-methyl-testosterone, 17α-ethyl-19-nor-testosterone and 1-methyl-17β-hydroxy-androst-1-en-3-one. Corticosterone production was decreased with 17α-ethinyl-19-nor-testosterone in spite of an unchanged adrenal weight. The relative corticosterone production rate (μg/60 min · 100 mg adrenal) was in any cases unaffected. According to these results there exists – with the exception of 17α-ethinyl-19-nor-testosterone – a strict parallelism between corticosteroid turnover and corticosterone production rate: unchanged turnover is correlated with unchanged corticosterone production rate, while a decreased turnover is correlated with decreased adrenal activity. The protein-anabolic effect of certain anabolic steroids may be partly due to an anti-catabolic action of these compounds resulting from a decreased corticosteroid inactivation and production rate. Possible mechanisms by which anabolic steroids may affect corticosteroid-balance are discussed.

Sign in / Sign up

Export Citation Format

Share Document